Please wait while the formulary information is being retrieved.
PLUVICTO (lutetium Lu-177 vipivotide tetraxetan)
- PSMA(+) metastatic castration-resistant prostate cancer
27 mCi/mL (1,000 MBq/mL) intravenous solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- None
Contraindicated
- Anemia
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Abnormal hepatic function tests
- Chronic kidney disease stage 2 (mild) GFR 60-89 ml/min
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
PLUVICTO (lutetium Lu-177 vipivotide tetraxetan)
- PSMA(+) metastatic castration-resistant prostate cancer
- Anemia
- Hypocalcemia
- Hyponatremia
- Lymphopenia
- Thrombocytopenic disorder
- Anorexia
- Constipation
- Fatigue
- Nausea
- Xerostomia
More Frequent
Severe
Less Severe
- Hemorrhage
- Kidney disease with reduction in GFR
- Neutropenic disorder
- Pneumonia
- Sepsis
- Acute abdominal pain
- Diarrhea
- Dizziness
- Dry eye
- Dysgeusia
- Fever
- Headache disorder
- Musculoskeletal pain
- Peripheral edema
- Urinary tract infection
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cerebrovascular accident
- Hepatic failure
- Intracranial bleeding
- Pulmonary thromboembolism
- Spinal cord compression
- Subdural intracranial hemorrhage
Less Severe
- Infertility
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lutetium-177 vipivotide tetraxetan
Safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years.
Lutetium Lu 177 Vipivotide Tetraxetan
- Severity Level:
D
- Additional Notes: Theoretical risk based on moa; insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Lutetium Lu 177 Vipivotide Tetraxetan
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Lutetium Lu-177 Vipivotide Tetraxetan
General-Patients greater than 74 years have higher rates of Grade 3 and 4 adverse reactions compared to younger patients.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| PSMa(+) metastatic castration-resistant prostate cancer | |
| C61 | Malignant neoplasm of prostate |
| Z19.2 | Hormone resistant malignancy status |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
| Z19.2 | Hormone resistant malignancy status |
Formulary Reference Tool